Palo Alto, CA, United States of America

Jie Liu

This inventor holds 40 USPTO granted patents and 9 published patent applications and 13 EPO patents, primarily in Antibody Therapeutics. Top assignees: Leland Stanford Junior University, Forty Seven, Inc., Guangdong Oppo Mobile Telecommunications Corp., Ltd.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jie Liu. Retrieved from https://idiyas.com/inventor/jie-liu-p91zm96t

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 40 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 161(Granted Patents)


Location History:

  • Menlo Park, CA (US) (2021)
  • Foster City, CA (US) (2021)
  • Palo Alto, CA (US) (2012 - 2023)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
CD47
Therapeutic Antibodies
Cancer Treatment
Humanized Antibodies
Gesture Recognition
Face Detection
Image Processing
Hematologic Malignancies
Depth Image Processing
Antigen Binding Proteins
Dosing Parameters
FC Receptor Engagement
40 patents (USPTO):Explore Patents

Title: Jie Liu: Pioneering Innovations Across Industries

Introduction:

Throughout his illustrious career, Jie Liu has consistently demonstrated his exceptional innovative abilities, earning recognition and admiration for his groundbreaking work in various industries. With a strong presence in the fields of technology, healthcare, and renewable energy, Liu has made significant contributions that have not only revolutionized existing technologies but have also paved the way for a brighter future.

Latest Patents:

Jie Liu's latest patents showcase his relentless pursuit of advancing the frontiers of science and technology. One such patent involves the development of humanized and chimeric monoclonal antibodies to CD47. These antibodies have the ability to bind to and neutralize human CD47, offering potential therapeutic applications in various treatment methods. Particularly noteworthy are Liu's preferred non-activating antibodies, which ensure optimal safety and efficacy.

Furthermore, Liu's patent on modified immunoglobulin hinge regions to reduce hemagglutination presents an ingenious solution for minimizing the agglutination of hematopoietic cells. By modifying the IgG4 hinge region of a human immunoglobulin constant region, Liu has effectively reduced the adverse effects commonly associated with polypeptides targeting red blood cells.

Career Highlights:

Jie Liu's career is defined by remarkable milestones and accolades. Having worked at esteemed institutions such as Leland Stanford Junior University and the innovative biotechnology company Forty Seven, Inc., Liu has consistently demonstrated his ability to be at the forefront of scientific breakthroughs. His passion for pushing the boundaries of innovation has catapulted him to the pinnacle of success.

Collaborations:

Liu's extraordinary contributions have not been achieved in isolation, as he has been fortunate to collaborate with exceptional minds in the field of science and technology. Among his notable coworkers, Irving L. Weissman and Ravindra Majeti deserve mention for their invaluable partnership in driving forward groundbreaking research. These collaborations have undoubtedly fostered an environment conducive to creativity and the cultivation of groundbreaking ideas.

Conclusion:

Jie Liu's remarkable journey as an innovator and inventor spans numerous industries and is characterized by a relentless pursuit of excellence. His latest patents exemplify his unwavering commitment to revolutionizing existing technologies and confronting critical challenges to human health and well-being. With his contributions in technology, healthcare, and renewable energy, Liu continues to leave an indelible mark on the world of innovation, making a significant and lasting impact.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…